Cognitive Impairment and Upper Extremity Performance in COPD

NCT05137483 | Unknown

• 1 other identifier: IKC125
• Study Type: observational
• Target: 80
• Locations: 0 countries
• Sites: N/A

Brief Summary

Within the scope of this study, COPD patients will be divided into two groups according to cognitive dysfunction. Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the groups.

Conditions

COPD; Upper Extremity; Upper Limb Function; Cognitive Impairment

Keywords

copd; cognitive impairment; cognition; upper extremity

Outcome Measures

Primary Outcomes (1)

• 6 min. pegboard ring test

  It is used to measure upper extremity functional capacity.

  6 minutes

Secondary Outcomes (7)

• Mini Mental State Test

  15 minutes

• Montreal Cognitive Assessment Scale

  30 minutes

• Respiratory Function Test

  20 minutes

• Fatigue Impact Scale

  Time Frame: 20 minutes

• St. George Respiratory Questionnaire

  20 minutes

Study Arms (2)

With cognitive impairment

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.

Other: Functional tests

without cognitive impairment

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.

Other: Functional tests

Interventions

Functional tests OTHER

We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.

With cognitive impairment; without cognitive impairment

Eligibility Criteria

• Age: 45 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

COPD patients above 45 years

You may qualify if:

• Volunteering to participate in the study
• Stage 2-3-4 according to the GOLD classification in the 40-65 age range

You may not qualify if:

• Exacerbation of respiratory symptoms in the past 4 weeks (change in breathlessness and/or sputum volume/color, need for antibiotic treatment or need for hospitalization)
• Presence of asthma, unstable coronary heart disease, uncontrolled diabetes, hypertension, left-sided congestive heart failure, neoplasia, severe claudication, encephalitis or epilepsy
• Having a history of head trauma or brain tumor
• Having a significant psychiatric condition or the presence of defined dementia, according to the American Psychiatric Association

Sponsors & Collaborators

• Izmir Katip Celebi University: lead

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc. Prof

Study Record Dates

• First Submitted: November 18, 2021
• First Posted: November 30, 2021
• Study Start: November 19, 2021
• Primary Completion: June 30, 2022
• Study Completion: July 30, 2022
• Last Updated: November 30, 2021

Record last verified: 2021-11

Data Sharing

• IPD Sharing: Will not share